Blueprint Medicines Corp (BPMC)
129.46
0.00 (0.00%)
USD |
NASDAQ |
Aug 13, 16:00
Blueprint Medicines PS Ratio
PS Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical PS Ratio Data
| Date | Value |
|---|---|
| August 13, 2025 | 14.76 |
| August 12, 2025 | 14.76 |
| August 11, 2025 | 14.76 |
| August 08, 2025 | 14.76 |
| August 07, 2025 | 14.76 |
| August 06, 2025 | 14.76 |
| August 05, 2025 | 14.76 |
| August 04, 2025 | 14.76 |
| August 01, 2025 | 14.76 |
| July 31, 2025 | 14.76 |
| July 30, 2025 | 14.76 |
| July 29, 2025 | 14.76 |
| July 28, 2025 | 14.76 |
| July 25, 2025 | 14.76 |
| July 24, 2025 | 14.76 |
| July 23, 2025 | 14.76 |
| July 22, 2025 | 14.76 |
| July 21, 2025 | 14.76 |
| July 18, 2025 | 14.76 |
| July 17, 2025 | 14.76 |
| July 16, 2025 | 14.74 |
| July 15, 2025 | 14.75 |
| July 14, 2025 | 14.75 |
| July 11, 2025 | 14.74 |
| July 10, 2025 | 14.75 |
| Date | Value |
|---|---|
| July 09, 2025 | 14.66 |
| July 08, 2025 | 14.64 |
| July 07, 2025 | 14.64 |
| July 03, 2025 | 14.63 |
| July 02, 2025 | 14.62 |
| July 01, 2025 | 14.63 |
| June 30, 2025 | 14.61 |
| June 27, 2025 | 14.61 |
| June 26, 2025 | 14.61 |
| June 25, 2025 | 14.62 |
| June 24, 2025 | 14.62 |
| June 23, 2025 | 14.64 |
| June 20, 2025 | 14.62 |
| June 18, 2025 | 14.61 |
| June 17, 2025 | 14.62 |
| June 16, 2025 | 14.62 |
| June 13, 2025 | 14.59 |
| June 12, 2025 | 14.62 |
| June 11, 2025 | 14.59 |
| June 10, 2025 | 14.59 |
| June 09, 2025 | 14.59 |
| June 06, 2025 | 14.58 |
| June 05, 2025 | 14.58 |
| June 04, 2025 | 14.61 |
| June 03, 2025 | 14.55 |
Price to Sales Ratio Definition
The Price to Sales Ratio (PS Ratio) is calculated by taking the stock price / revenue per share (ttm). This metric is considered a valuation metric that confirms whether the sales of a company justifies the stock price. There isn't necesarily an optimum PS ratio, since different industries will have different ranges of PS Ratios. Because of this, PS Ratio is great to evaluate from a relative standpoint with other similar companies. PS Ratio might also be a handy metric for companies that are not profitable yet, since they might be valued moreso by their overall sales and potential of becoming profitable in the future.
PS Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
PS Ratio Benchmarks
| Agenus, Inc. | 1.994 |
| Amgen, Inc. | 5.573 |
| Altimmune, Inc. | 13365.25 |
| Amarantus Bioscience Holdings, Inc. | -- |
| Aligos Therapeutics, Inc. | 1.890 |
PS Ratio Related Metrics
| Price | 129.46 |